Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Blood·2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

HemaSphere·2026

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia·2026

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.

Blood advances·2026

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

European journal of cancer (Oxford, England : 1990)·2026

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026

Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study.

The Lancet. Oncology·2026

Burden of cancer in Africa, 1990-2023: a systematic analysis from the Global Burden of Disease Study 2023.

The Lancet. Oncology·2026

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

The Lancet. Oncology·2026

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

The Lancet. Oncology·2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

The Lancet. Oncology·2026

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2026

Integrated Traditional Chinese and Western Medicine for Severe Tislelizumab-Induced Rash: A Case Report.

Case reports in oncology·2026

Glucocorticoids combined with rituximab treatment for IgG4-related tubulointerstitial nephritis with diabetic nephropathy: a case report.

Open medicine (Warsaw, Poland)·2026

Quality Assessment of an Immunotherapy Toxicity Clinic: A Clinical Audit at Castle Hill Hospital Evaluating Adherence to Clinical Guidelines, Documentation Standards, and Clinical Outcomes.

Cureus·2026

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

Human pathology·2026

CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.

Cancer letters·2026

Effects of anion excipients on the viscosity of high-concentration mAb solution.

Journal of pharmaceutical sciences·2026

Related Experiment Videos

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

Related Concept Videos

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study.

Burden of cancer in Africa, 1990-2023: a systematic analysis from the Global Burden of Disease Study 2023.

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Integrated Traditional Chinese and Western Medicine for Severe Tislelizumab-Induced Rash: A Case Report.

Glucocorticoids combined with rituximab treatment for IgG4-related tubulointerstitial nephritis with diabetic nephropathy: a case report.

Quality Assessment of an Immunotherapy Toxicity Clinic: A Clinical Audit at Castle Hill Hospital Evaluating Adherence to Clinical Guidelines, Documentation Standards, and Clinical Outcomes.

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.

Effects of anion excipients on the viscosity of high-concentration mAb solution.

Related Experiment Videos

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

Related Concept Videos

Related Articles